Effects of anticancer agents on cell viability,proliferative activity and cytokine production of peripheral blood mononuclear cells |
| |
Authors: | Hiromi Sakai Satoshi Kokura Takeshi Ishikawa Reiko Tsuchiya Manabu Okajima Tatsuzou Matsuyama Satoko Adachi Kazuhiro Katada Kazuhiro Kamada Kazuhiko Uchiyama Osamu Handa Tomohisa Takagi Nobuaki Yagi Yuji Naito Toshikazu Yoshikawa |
| |
Affiliation: | 1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan;2Department of Cancer ImmunoCell Regulation, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan |
| |
Abstract: | We investigated the effects of anticancer agents on peripheral blood mononuclear cells for the purpose of providing data to support new translational chemoimmunotherapy regimens. Peripheral-blood mononuclear cells were treated with one of four anticancer agents (5-fluorouracil, irinotecan, cisplatin, and gemcitabine) for 2 h, after which cell viability was determined. For assessment of effects of each drug on proliferation and cytokine production, cells were stimulated with phytohemagglutinin for 48 h. As a result, the anticancer agents did not affect cell viability. Cell proliferation was unaffected by 5-fluorouracil and irinotecan but inhibited by cisplatin and gemcitabine. Treatment with gemcitabine enhanced the production of IFN-γ and decreased the number of regulatory T cells. gemcitabine treatment increased IFN-γ production among CD4 T cells but not among CD8 T cells. The results indicated that GEM had immunoregulatory properties that might support immune response against cancer. This finding has implications for designing chemoimmunotherapy strategies. |
| |
Keywords: | chemoimmunotherapy 5-fluorouracil (5-FU) irinotecan (CPT-11) cisplatin (CDDP) gemcitabine (GEM) |
|
|